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ABSTRACT
We have previously developed a genetically-engineered GFP-expressing 
telomerase-dependent adenovirus, OBP-401, which can selectively illuminate cancer 
cells. In the present report, we demonstrate that targeting a triple-negative high-
invasive human breast cancer, orthotopically-growing in nude mice, with OBP-401 
enables curative fluorescence-guided surgery (FGS). OBP-401 enabled complete 
resection and prevented local recurrence and greatly inhibited lymph-node metastasis 
due to the ability of the virus to selectively label and subsequently kill cancer cells. In 
contrast, residual breast cancer cells become more aggressive after bright (white)-
light surgery (BLS). OBP-401-based FGS also improved the overall survival compared 
with conventional BLS. Thus, metastasis from a highly-aggressive triple-negative 
breast cancer can be prevented by FGS in a clinically-relevant mouse model.
INTRODUCTION
Triple-negative breast cancers (TNBC) are defined 
by a lack of expression of estrogen, progesterone, 
and ERBB2 receptors, and are the most aggressive 
and metastatic breast cancer. The absence of effective 
treatment for this recalcitrant disease lead to a higher 
rate of local and systemic relapse after primary tumor 
resection.
Fluorescence-guided surgery (FGS) is an area of 
intense research [1]. Green fluorescent protein (GFP) has 
been previously successfully used for targeting tumors in 
situ for FGS using a telomerase-dependent adenovirus 
(OBP-401) that expresses the gfp gene only in cancer 
cells [1–7]. Since recurrent cancer cells stably express 
GFP, detection of cancer recurrence and metastasis is also 
possible with OBP-401 GFP labeling [7], in contrast to 
fluorescent-antibody or other non-genetic labeling [1].
We have previously demonstrated OBP-401-
based fluorescence-guided surgery is highly effective in 
various types of cancers including soft tissue sarcoma [4], 
glioblastoma [5], pancreatic cancer [6], lung cancer [7], 
colon cancer-liver metastasis [8], and melanoma [9]. In 
contrast, conventional bright-light surgery (BLS) could 
not fully resect these tumors [4–9].
In the present study, we describe that OBP-401 
targets a high-metastatic variant of triple-negative human 
breast cancer, an aggressive recalcitrant cancer, in nude 
mice and enables complete resection, prevents recurrence 
and improves disease-free survival and over-all survival. 
The clinical implications of these results are discussed.
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RESULTS AND DISCUSSION
GFP-expressing adenovirus OBP-401 labels low- 
and high-invasive breast cancer cells in vitro
Firstly, we confirmed whether OBP-401 could label 
low- (parental) and high-invasive MDA-MB-231-RFP 
breast cancer cells in vitro. Time course imaging showed 
that OBP-401 labeled low- and high-invasive MDA- 
MB-231-RFP breast cancer cells with GFP (Figure 1A). 
OBP-401 labeled low- and high-invasive MDA-MB-231- 
RFP breast cancer cells in a dose-dependent manner 
(Figure 1B).
Figure 1: OBP-401 labels low- and high-invasive MDA-MB-231-RFP breast cancer cells in vitro. Low- and high-invasive 
variants of MDA-MB-231-RFP cells were seeded in 6-well plates (1 × 105 cells a well). OBP-401 was added at the indicated multiplicity 
of infection (MOI) 24 hours after seeding. Images were acquired with a confocal laser scanning microscope FV1000 (Olympus, Tokyo, 
Japan). A. Representative images of low- and high-invasive MDA-MB-231-RFP breast cancer cells 3, 4, and 5 days after infection of OBP-
401 at the indicated MOI B. Histogram shows the frequency of GFP-expressing parental and highly metastatic MDA-MB-231-RFP breast 
cancer cells at indicated days after infection of OBP-401. The number of GFP-expressing cells was counted. Data are shown as average ± 
SD. N = 5.
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Bright-light surgery results in residual cancer 
cells
We performed bright (white) light surgery (BLS) 
on orthotopic low- and high-invasive MDA-MB-231-RFP 
in nude mice (Figures 2A, 2C). High-invasive MDA-
MB-231-RFP cells invaded the normal mammary gland, 
making the tumor margin invisible, thereby resulting 
in many cancer cells in the surgical field after BLS 
(Figure 2C). 
OBP-401-based fluorescence-guided surgery 
(OBP-401 FGS) enables resection of residual 
cancer cells
In situ OBP-401 labeling enabled tumor margins 
to be visualized (Figures 2B, 2D) and enabled tumor 
resection without residual cancer cells (Figure 2E). The 
time course of the FGS procedure for the high-invasive 
MDA-MB-231 variant is shown in Figure 3, using the 
portable Dino-Lite fluorescence scope. Confocal imaging 
visualized the resected tumor at the single-cell level.
Figure 2: Comparison of OBP-401-based fluorescence-guided surgery with bright-light surgery for orthotopic low- 
and high-invasive MDA-MB-231-RFP. OBP-401 was injected intaratumorally at 1 × 108 PFU when tumors reached approximately 
10 mm3 (diameter; 3 mm). A. Representative whole-tumor images of low-invasive MDA-MB-231-RFP cells before and after bright light 
surgery (BLS). White arrows point to the residual tumor. B. Representative whole-tumor images of low-invasive MDA-MB-231-RFP 
before injection of OBP-401, before and after OBP-401-based fluorescence-guided surgery (OBP-401 FGS).
(Continued )
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Figure 2 (Continued ): C. Representative whole-tumor images of high-invasive MDA-MB-231-RFP before and after BLS. D. 
Representative whole-tumor images of high-invasive MDA-MB-231-RFP before injection of OBP-401 and before and after OBP-401-
based fluorescence-guided surgery (OBP-401 FGS). E. Histogram shows the comparison of fluorescent area (left) and fluorescence intensity 
(right) of residual tumor in the surgical bed after BLS or OBP-401 FGS of low- and high-invasive MDA-MB-231-RFP. Fluorescence 
intensity and fluorescent area were calculated with ImageJ software. Data are shown as average ± SD. N = 10.
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Figure 3: In situ OBP-401 GFP-labeling visualizes invading cancer cells and enables complete resection of high-invasive 
MDA-MB-231-RFP. A. Representative high-magnification images of high-invasive MDA-MB-231-RFP before and after OBP-401 FGS 
using the hand-held fluorescence Dino-Lite scope. B. Step-by-step procedure of OBP-401 FGS for high-invasive MDA-MB-231-RFP (see 
Supplementary Movie S1). C. Representative images of en bloc tumor resected by OBP-401 FGS. Representative images of invading cancer 
cells resected by OBP-401 FGS visualized at the single-cell level using a confocal laser-scanning microscope (FV1000, Olympus, Tokyo, 
Japan).
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OBP-401 enables detection and FGS of residual 
breast cancer after BLS
OBP-401 GFP labeling detected high-invasive 
MDA-MB-231-RFP cells invading a lymphatic duct 
not otherwise detected (Figures 4A, 4B). OBP-401 also 
enabled detection of residual breast-cancer cells at the 
single-cell level after BLS (Figure 4C). We were able to 
precisely remove the residual breast-cancer cells after 
BLS using OBP-401 FGS with a minimum resection area 
(Figure 4D).
Figure 4: Sequential BLS and OBP-401 FGS of high-invasive MDA-MB-231-RFP. OBP-401 was injected intaratumorally at 
1 × 108 PFU when tumors reached approximately 10 mm3 (diameter; 3 mm). The labeled orthotopic tumor was initially resected by BLS and 
then residual tumor was resected by FGS. A. Representative high-magnification images of invading cancer cells in a lymphatic duct after 
BLS. B. Representative macroscopic images of incomplete resection of the tumor after BLS (before OBP-401 FGS). C. Representative 
high-magnification images of surgical area after sequential BLS and OBP-401 FGS. D. Representative microscopic image of resected 
residual tumor after OBP-401 FGS acquired with confocal laser scanning microscope FV1000 (Olympus, Japan).
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BLS results in recurrence and FGS does not
We compared the rate of local recurrence after OBP-
401 FGS or BLS alone for the high- and low-invasive 
MDA-MB-231-RFP tumor. With the low-invasive MDA-
MB-231-RFP tumor after BLS, 5 of 12 mice recurred 
locally and 2 of 10 had lymph-node metastasis. With the 
high-invasive MDA-MB-231-RFP, 10 of 12 mice recurred 
locally and 10 of 12 also had lymph-node metastasis after 
BLS. After FGS, none of the 12 low-invasive MDA-MB-
231-RFP recurred locally or distantly and, with the high-
invasive MDA-MB-231-RFP, none recurred locally and 2 
recurred distantly out of 14 total (Figure 5, Table 1).
Figure 5: OBP-401-based FGS controls local recurrence of high- and low-invasive MDA-MB-231-RFP. A. Representative 
whole-body images 150 days after BLS of low-invasive MDA-MB-231-RFP. Arrows indicate growing tumors. B. Representative whole 
body images 150 days after OBP-401 FGS for low-invasive MDA-MB-231-RFP. C. Comparison of fluorescent area of local recurrent 
tumors after BLS or OBP-401 FGS for low-invasive MDA-MB-231-RFP (right). Comparison of fluorescence intensity of local and 
metastatic tumors after BLS or OBP-401 FGS for low-invasive MDA-MB-231-RFP (left). D. Kaplan-Meyer shows disease-free survival 
after BLS or OBP-401 FGS for low-invasive MDA-MB-231-RFP.
(Continued )
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Figure 5 (Continued ): E. Representative whole-body images 120 days after BLS for high-invasive MDA-MB-231-RFP. Arrows indicate 
growing tumors. F. Representative whole-body images 120 days after OBP-401 FGS of high-invasive MDA-MB-231-RFP. G. Comparison 
of fluorescent area of local recurrent tumors after BLS or OBP-401 FGS for high-invasive MDA-MB-231-RFP (right). Comparison of 
fluorescence intensity of local recurrent tumors after BLS or OBP-401 FGS for high-invasive MDA-MB-231-RFP (left). H. Kaplan-Meyer 
curve shows disease-free survival after BLS or OBP-401 FGS for high-invasive MDA-MB-231-RFP. Fluorescent area and fluorescence 
intensity were calculated with ImageJ software. Data are shown as average ± SD.
Comparison of survival
After FGS with the low-invasive MDA-MB-231-
RFP, all mice were alive at 150 days, in contrast to 60% 
of the mice receiving BLS. With the high-invasive MDA-
MB-231-RFP tumor, 80% of the mice were alive at 150 
days with FGS and only 10% with BLS (Figure 6).
In the present report, we demonstrate that high-
invasive triple-negative breast cancer (TNBC) can be 
cured by OBP-401-based FGS, in contrast to standard 
BLS, which cannot cure this disease, in orthotopic 
nude mouse models. The present results demonstrate 
that recurrence of even a highly-invasive TNBC can be 
prevented in a clinically-relevant mouse model by FGS. 
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Table 1: Efficacy of BLS or FGS on high- and low-invasive triple-negative breast cancer
Local recurrence Positive Negative Lymph node metastasis recurrence Positive Negative
BLS
Low-invasive 5 7
BLS
Low-invasive 2 10
OBP-401 FGS
Low-invasive 0 12*
OBP-401 FGS
Low-invasive 0 12
BLS
High-invasive 10 2
BLS
High-invasive 10 2
OBP-401 FGS
High-invasive 0 12**
OBP-401 FGS
High-invasive 2 10***
*P=0.012; **P<0.001; ***P<0.001
Figure 6: OBP-401-based FGS inhibits metastatic recurrence. A. Representative whole-body images 150 days after BLS for low-
invasive MDA-MB-231-RFP. Arrows indicate growing metastatie tumors. B. Representative whole-body images 150 days after OBP-401 
FGS for low-invasive MDA-MB-231-RFP. C. Comparison of fluorescent area of lymph-node metastasis after BLS or OBP-401 FGS for 
low-invasive MDA-MB-231-RFP (right). Comparison of fluorescence intensity of lymph-node metastasis after BLS or OBP-401 FGS for 
low-invasive MDA-MB-231-RFP (left). D. Kaplan-Meyer curve shows the overall survival after BLS or OBP-401 FGS of low-invasive breast 
cancer.
(Continued )
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Figure 6 (Continued ): E. Representative whole-body images 120 days after BLS for high-invasive MDA-MB-231-RFP. Arrows 
indicate growing metastatic tumors. F. Representative whole-body images 120 days after OBP-401 FGS for high-invasive MDA-MB-
231-RFP. G. Comparison of fluorescent area of lymph node metastasis after BLS or OBP-401 FGS for high-invasive MDA-MB-231-RFP 
(right). Comparison of fluorescence intensity of l lymph node metastasis after BLS or OBP-401 FGS for high-invasive MDA-MB-231-RFP 
(left). H. Kaplan-Meyer curve shows the overall survival after BLS or OBP-401 FGS of high-invasive MDA-MB-231-RFP. Fluorescent 
area and fluorescence intensity were calculated with ImageJ software. Data are shown as average ± SD.
Our results thereby indicate the clinical potential of 
OPB-401-based FGS for highly-aggressive cancer. OBP-
401-based FGS can also be applied to liver metastasis 
resection [8] and other metastatic disease. FGS can also 
be performed with chemically-activable fluorescent probes 
[10–13] that can be used in a complementary manner with 
OBP-401 to ensure all cancer cells can be visualized by 
the surgeon, including recurrent disease.
Previously developed concepts and strategies of 
highly-selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [14–19].
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MATERIALS AND METHODS
Animal experiments
Athymic nude mice (AntiCancer Inc., San Diego, 
CA) were used in this study. Mice were fed with autoclaved 
laboratory rodent diet (Tecklad LM-485, Western Research 
Products). All animal studies were conducted in accordance 
with the principals and procedures outlined in the National 
Institutes of Health Guide for the Care and Use of Laboratory 
Animals under assurance A3873-01. All animal studies were 
conducted with an AntiCancer Institutional Animal Care and 
Use Committee (IACUC)-protocol specifically approved 
for this study. In order to minimize any suffering of the 
animals, anesthesia and analgesics were used for all surgical 
experiments. Animals were anesthetized by intramuscular 
injection of a 0.02 ml solution of 20 mg/kg ketamine, 15.2 
mg/kg xylazine, and 0.48 mg/kg acepromazine maleate. The 
response of animals during surgery was monitored to ensure 
adequate depth of anesthesia. Ibuprofen (7.5 mg/kg orally in 
drinking water every 24 hours for 7 days post-surgery) was 
used in order to provide analgesia post-operatively in the 
surgically-treated animals. The animals were observed on a 
daily basis and humanely sacrificed by CO2 inhalation if they 
met the following humane endpoint criteria: prostration, skin 
lesions, significant body weight loss, difficulty breathing, 
epistaxis, rotational motion and body temperature drop. 
The use of animals was necessary to develop fluorescence-
guided surgery of highly-metastatic triple-negative breast 
cancer. Mice were housed with no more than 5 per cage. 
Mice were housed in a barrier facility on a high-efficiency 
particulate arrestance (HEPA)-filtered rack under standard 
conditions of 12-hour light/dark cycles. The animals were 
fed an autoclaved laboratory rodent diet.
GFP-expressing telomerase-specific adenovirus
The recombinant GFP-expressing, cancer-specific, 
replication-selective adenovirus vector OBP-401, has 
the promoter element of the human telomerase reverse- 
transcriptase (hTERT) gene which drives the expression 
of E1A and E1B genes linked to an internal ribosome 
entry site for selective replication only in cancer cells. 
The GFP gene is driven by the CMV promoter. The virus 
was constructed and produced as previously described [2-
9, 20, 21].
Cell culture
The human triple-negative breast cancer cell line, 
MDA-MB-231 [22, 23] was maintained and cultured 
in DMEM with 10% fetal bovine serum (FBS) and 
5% penicillin/streptomycin. Highly-metastatic MDA-
MB-231 cells, expressing red fluorescent protein (MDA-
MB-231-RFP), derived from a lymph-node metastasis 
after orthotopic transplantation in nude mice were also 
maintained and cultured in DMEM with 10% fetal bovine 
serum (FBS) and 5% penicillin/streptomycin.
In vivo whole body/whole-tumor and cellular 
imaging
The OV100 small animal imaging system (Olympus 
Corp., Tokyo, Japan), was used. The OV100 contains an MT-
20 light source (Olympus Biosystems, Planegg, Germany) 
and DP70 CCD camera (Olympus), for subcellular imaging 
in live mice. The optics of the OV100 have been specially 
developed for macroimaging as well as microimaging with 
high light-gathering capacity. The instrument incorporates 
a unique combination of high numerical aperture and long 
working distance. Four individually-optimized objective 
lenses, parcentered and parfocal, provide a 105-fold 
magnification range for seamless imaging of the entire body 
down to the subcellular level without disturbing the animal 
[24]. The FV1000 scanning laser confocal microscope 
(Olympus, Tokyo, Japan) was used for cellular imaging of 
resected tumors [25]. 
OBP-401 based fluorescence-guided surgery 
(OBP-401 FGS)
All animal procedures were done under anesthesia 
using s.c. administration of a ketamine mixture (see 
above). After skin incision, the OBP-401-GFP-labeled 
tumor was visualized with the OV100 [2-9, 20, 21]. The 
tumor was resected under fluorescence-guidance using the 
Dino-Lite (AM4113T-GFBW Dino-Lite Premier; AnMo 
Electronics Corp., Hsinchu, Taiwan), a hand-build scope 
[26]. After tumor resection, if there was residual tumor, a 
second resection was performed. After surgery, the skin 
incision was closed with a 6-0 suture.
Statistical analysis
Data are shown as means ± standard deviation (SD). 
For comparison between two groups, significant differences 
were determined using Student’s t-test. P values of < 0.05 
were considered significant. For comparison of more than 
two groups, statistical significance was determined with 
a one-way analysis of variance (ANOVA) followed by 
a Bonferroni multiple group comparison test. Pearson 
chi-square analysis was used to evaluate the rate of local 
recurrence, lymph node metastasis between BLS and OBP-
401 FGS of parental MDA-MB-231 and high-metastatic 
MDA-MB-231 tumors. Statistical analysis for disease-
free survival and overall survival was performed using the 
Kaplan-Meier test along with log-rank test.
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